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ABSTRACT
Objective Epidermal growth factor receptor (EGFR) 
inhibition may be effective in biomarker- selected 
populations of advanced gastro- oesophageal 
adenocarcinoma (aGEA) patients. Here, we tested the 
association between outcome and EGFR copy number 
(CN) in pretreatment tissue and plasma cell- free DNA 
(cfDNA) of patients enrolled in a randomised first- line 
phase III clinical trial of chemotherapy or chemotherapy 
plus the anti- EGFR monoclonal antibody panitumumab 
in aGEA (NCT00824785).
Design EGFR CN by either fluorescence in situ 
hybridisation (n=114) or digital- droplet PCR in tissues 
(n=250) and plasma cfDNAs (n=354) was available 
for 474 (86%) patients in the intention- to- treat (ITT) 
population. Tissue and plasma low- pass whole- genome 
sequencing was used to screen for coamplifications 
in receptor tyrosine kinases. Interaction between 
chemotherapy and EGFR inhibitors was modelled in 
patient- derived organoids (PDOs) from aGEA patients.
Results EGFR amplification in cfDNA correlated with 
poor survival in the ITT population and similar trends 
were observed when the analysis was conducted in 
tissue and plasma by treatment arm. EGFR inhibition 
in combination with chemotherapy did not correlate 
with improved survival, even in patients with significant 
EGFR CN gains. Addition of anti- EGFR inhibitors to 
the chemotherapy agent epirubicin in PDOs, resulted 
in a paradoxical increase in viability and accelerated 
progression through the cell cycle, associated with p21 
and cyclin B1 downregulation and cyclin E1 upregulation, 
selectively in organoids from EGFR- amplified aGEA.
Conclusion EGFR CN can be accurately measured 
in tissue and liquid biopsies and may be used for 
the selection of aGEA patients. EGFR inhibitors may 
antagonise the antitumour effect of anthracyclines 
with important implications for the design of future 
combinatorial trials.
Significance of this study
What is already known on this subject?
 ► Clinical trials combining epidermal 
growth factor receptor (EGFR) inhibitors 
and chemotherapy for advanced gastro- 
oesophageal adenocarcinomas (GEAs) have 
failed in unselected patient populations.
 ► Anecdotal data suggest that EGFR amplification 
might predict benefit from EGFR inhibitors in 
advanced GEA.
 ► Heterogeneous expression of biomarkers is 
an intrinsic characteristic of GEA and analysis 
of liquid biopsies as a tool to overcome 
intrapatient heterogeneity is warranted.
What are the new findings?
 ► We tested EGFR copy number in tissue and 
liquid biopsies from advanced GEA patients 
enrolled in a prospective randomised phase III 
trial of chemotherapy alone or chemotherapy 
plus the anti- EGFR monoclonal antibody 
panitumumab.
 ► EGFR status could be reliably detected in tissue 
and liquid biopsies and concordance between 
the two was observed in 95% of cases.
 ► EGFR amplification in tissue and circulating 
cell- free DNA appeared as a negative 
prognostic marker in the intention- to- treat 
population and in individual treatment arms.
 ► EGFR- amplified cases treated with EGFR 
inhibitors in combination with chemotherapy 
had a particularly poor prognosis. Using 
patient- derived organoids, we showed an 
antagonistic effect between anti- EGFR 
agents and the chemotherapy drug epirubicin 
specifically in EGFR- amplified organoids.
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INTRODUCTION
Amplification of receptor tyrosine kinases is a hallmark of gastric 
and oesophageal adenocarcinomas, with epidermal growth 
factor receptor (EGFR) amplification occurring in 6%–10% of 
gastro- oesophageal adenocarcinomas (GEAs).1–3 Although there 
is level 1 evidence supporting treatment of GEA and breast 
tumours which harbour amplifications of human epidermal 
growth factor receptor 2 (HER2) with anti- HER2 therapy, the 
effect of targeting the EGFR axis in EGFR- amplified tumours is 
less well established.4–6 Two large randomised trials, REAL3 and 
EXPAND, evaluated the efficacy of addition of anti- EGFR mono-
clonal antibodies (mAb) to cytotoxic chemotherapy in patients 
with unselected, treatment naïve advanced GEA.7 8 Neither 
trial demonstrated an improvement in survival for anti- EGFR 
treated patients in a non- biomarker selected patient popula-
tion. However, emerging translational analyses from unselected 
clinical trials and new early phase trials in biomarker- defined 
subgroups suggest that a population of EGFR- amplified GEA 
exist who might benefit from anti- EGFR therapy.2 9 If future 
clinical trials seek to evaluate the efficacy of anti- EGFR therapy 
in biomarker- enriched populations, understanding the interac-
tion between EGFR amplification and chemotherapy outcome is 
essential for rational trial design. Additionally, as heterogeneous 
expression of biomarkers is a fundamental characteristic of 
gastro- oesophageal cancers, analysis of liquid biopsies as a tool 
to overcome intrapatient heterogeneity is warranted.10 11
In this study, we tested the association between EGFR 
amplification and clinical outcome in patients treated with 
epirubicin, oxaliplatin and capecitabine plus or minus panitu-
mumab (EOX±P) in the REAL3 (randomised trial of EOX with 
or without panitumumab in Advanced or Locally Advanced 
Oesophagogastric Cancer 3) Trial (NCT00824785). EGFR status 
was tested by digital- droplet PCR (ddPCR) and fluorescent in 
situ hybridisation (FISH) in tumour samples and by ddPCR in 
plasma samples, and was correlated with progression free (PFS) 
and overall survival (OS) in the trial population. Patient- derived 
organoids (PDOs) from EGFR- amplified and non- amplified 
metastatic GEA patients12 13 were used for reverse translation in 




Details of the REAL3 trial have been previously described.8 
REAL3 eligible patients had a diagnosis of locally advanced or 
metastatic oesophagogastric cancer and were treated with EOX 
(epirubicin, oxaliplatin and capecitabine) plus or minus the fully 
human monoclonal IgG2 anti- EGFR antibody panitumumab. 
Patients treated with EOX plus panitumumab had inferior OS 
compared with patients treated with EOX (HR 1.37, 95% CI 
1.07 to 1.76; p=0.013). From the REAL3 patient population 
(n=553), pretreatment tumour biopsies (tissue blocks) with 
high tumour content (>30%) were selected by a pathologist. All 
patients included in this analysis had given informed consent for 
translational research. DNA was extracted from formalin fixed 
paraffin embedded (FFPE) pretreatment tumour biopsies using 
QIAamp DNA FFPE (Qiagen, Manchester, UK). Cell- free DNA 
(cfDNA) was extracted from two ml of patient plasma using 
the QIAamp DNA Blood Mini Kit (Qiagen, Manchester, UK). 
cfDNA was eluted in 50 µL of elution buffer and quantified 
using the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, 
Loughborough, UK).
Statistical methods
The objectives of the study were to test: (1) the sensitivity and 
specificity of EGFR testing by FISH vs ddPCR; (2) the correlation 
between EGFR status in solid (tissue) versus liquid (pretreatment 
cfDNA) biopsies; (3) the association between EGFR amplifica-
tion, PFS and OS in the intention to treat population (ITT) and 
in each arm of the study separately and (4) descriptive analysis 
of PFS and OS in EGFR amplified cases based on treatment arm.
We defined EGFR amplification as EGFR/CNTNAP2 ratio 
of ≥2 using ddPCR. Exploratory analyses also evaluated the 
effect of EGFR amplification when a higher cut- off was chosen 
for amplification (ddPCR ratio in tissue or plasma of ≥5.0). 
PFS and OS were estimated using the Kaplan- Meier method. 
Groups were compared using the log- rank test and Cox regres-
sion was used to generate HRs and 95% CIs. Response rates 
were compared between groups using logistic regression, which 
generated ORs and 95% CIs. In multivariate analysis, forward 
stepwise Cox regression was used to calculate corrected HRs and 
95% CIs. Statistical analyses were performed using Stata V.13 
(Timberlake Consultants, Richmond on Thames, UK).
Online supplemental methods can be found online.
RESULTS
Study population and EGFR copy number analysis
Of the 553 REAL3 participants, 272 tissue samples from 250 
patients and 370 pretreatment cfDNA samples from 354 patients 
were available for EGFR copy number variation (CNV) anal-
ysis either by FISH or ddPCR (figure 1A). In all patients with 
multiple tissue or cfDNA samples available, a 100% concor-
dance in EGFR CNV was observed across samples.
EGFR CNV FISH data on chemonaïve pretreatment tissue 
(resections or biopsies) were available in 114 out of 200 patients 
enrolled in the phase II portion of the REAL3 trial; reasons for 
no availability of results included: (1) lack of patient consent 
for analysis (n=10); (2) insufficient tumour tissue left following 
previous analyses (n=36); (3) technical failure (n=18); (4) other 
reasons for example, block returned to treating hospital (n=22). 
Of the 114 samples successfully tested, nine patients (7.9%) 
were found positive for EGFR amplification by FISH.
Using ddPCR, EGFR CNV score on pretreatment tissue was 
≥2.0 in 17/250 (6.8%), and ≥5.0 in 12/250 (4.8%) patients. 
DdPCR EGFR CNV score on pretreatment cfDNA was ≥2.0 
in 22/354 (6.2%) and ≥5.0 in 10/354 (2.8%) patients. Overall, 
cfDNA concentration appeared higher in metastatic compared 
with locally advanced cancers (p=0.08), while no significant 
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► Our study demonstrates the robustness and feasibility of 
biomarker testing in liquid biopsies of advanced gastro- 
oesophageal adenocarcinoma (GEA) patients. Liquid biopsies 
could be used in prospective trials for advanced GEA patients 
as a screening tool.
 ► Epidermal growth factor receptor inhibitors should not 
be combined with chemotherapy regimens containing 
anthracyclines with significant implications in GEA and other 
tumour types.
 ► Patient- derived preclinical models are of paramount 
importance in defining mechanisms of action of drug 
combinations.
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differences in cfDNA concentration were observed based on 
gender, localisation of the primary cancer (oesophagus, junction 
or stomach), or based on presence of lung or peritoneal metas-
tases. A small but significant difference in cfDNA concentration 
was, however, observed between patients with or without liver 
metastases (p=0.007) (online supplemental table 1).
Comparative EGFR CN analysis in solid and liquid biopsies
Comparison between EGFR CNV determined by FISH and 
ddPCR on tissue was available in 107 cases, while comparison 
between EGFR CNV determined by ddPCR both on tissue and 
cfDNA was possible in 170 cases. Finally, comparison among 
EGFR CNV determined by ddPCR on tissue and cfDNA, as well 
as by FISH on tissue, was available in 60 cases. Overall, EGFR 
CNV status using either FISH, or ddPCR on tissue or cfDNA, 
was available in 474 patients (85.7% of the ITT population) 
(figure 1B).
In situ hybridisation is considered the gold standard for 
the determination of HER2 CNV status in breast and gastro- 
oesophageal cancer14; we, therefore, used a similar approach 
for EGFR CNV status, and considered FISH as the reference. 
Concordance between EGFR CNV assessed by ddPCR and 
FISH on tumour tissue was 98%. Compared with FISH, ddPCR 
showed sensitivity of 1 (95% CI 0.61 to 1.00), specificity of 0.97 
(95% CI 0.92 to 0.99), positive predictive value of 0.81 (95% 
CI 0.47 to 0.96), and negative predictive value of 0.95 (95% CI 
0.95 to 1.00) (online supplemental table 2). Next, we compared 
EGFR CNV between matched pretreatment tissue and cfDNA 
samples, assessed by ddPCR. Overall, concordance was 94.7% 
(online supplemental table 3); six cases that scored as EGFR- 
amplified on tissue (3 of them with more than 12 EGFR copies) 
showed no amplification in cfDNA, while three cases showed 
EGFR amplification in cfDNA but not on the matched tissue. No 
significant differences in cfDNA concentration were observed in 
patients with or without EGFR amplification, suggesting that 
variable input of cfDNA is unlikely responsible for these discrep-
ancies (online supplemental figure 1). Finally, when EGFR status 
was tested in the 60 cases for which data by FISH and ddPCR 
on tissue, and by ddPCR on cfDNA were available, concordance 
between tissue and blood was 95%: 4 cases scored as EGFR- 
amplified and 53 cases as EGFR non- amplified by all the three 
methods, while in 3 cases an EGFR amplification was detected 
in tissue (by both FISH and ddPCR) but not in cfDNA (online 
supplemental table 4).
EGFR CN in tissue and prognosis in the REAL3 trial
Given the high concordance between EGFR status assessed by 
FISH and ddPCR on tissue samples, we performed a survival 
analysis on the 250 patients for whom ddPCR EGFR CNV data 
on tissue were available. Patient characteristics based on EGFR 
status in each treatment arm are shown in table 1. Patients 
whose tumours harboured EGFR- amplification (ddPCR CNV 
score ≥2) had a median PFS of 4.57 months (95% CI 2.5 to 
10.56 months), compared with 6.41 months (95% CI 5.99 to 
7.34 months) for non- amplified cases (HR 1.30 (95% CI 0.78 
to 2.16); p=0.32); a similar trend was observed when a higher 
threshold (ddPCR CNV score ≥5) was used for identifying 
EGFR- amplification (HR 1.70 (95% CI 0.92 to 3.12) p:0.09) 
(online supplemental table 5). Similar observations were drawn 
when the PFS analysis was conducted by treatment arm using 
both cut- offs (online supplemental table 6). In multivariate anal-
ysis adjusting for sex, age, performance status, disease status 
(locally advanced vs metastatic), and histological subtype, EGFR 
amplification retained a negative prognostic value regardless of 
treatment arm (EOX arm HR 1.3 (95% CI 0.5 to 2.9); EOX- 
P=1.3 (95% CI 0.7 to 2.5)).
Patients with EGFR- amplified tumours (ddPCR CNV score 
≥2) also had a lower median OS of 9.74 months (95% CI 3.68 to 
11.35 months), compared with 11.18 months for patients with 
EGFR non- amplified tumours (95% CI 8.78 to 13.16 months) 
(HR 1.28 (95% CI 0.77 to 2.13); p=0.35). A similar trend was 
observed when a higher cut- off (ddPCR CNV score ≥5) was 
applied in order to identify EGFR amplification (HR 1.5 (95% 
CI 0.82 to 2.79); p=0.47) (online supplemental table 7). Analo-
gous results were observed when the OS analysis was conducted 
by treatment arm for both cut- offs (online supplemental table 8).
Figure 1 Tissue and liquid biopsy analysis in the REAL3 trial. (A) Diagram shows the number of patients for whom FFPE tissues and plasma cfDNA 
were available for EGFR testing. (B) Venn diagram shows the number of patients tested for EGFR amplification based on source of material (FFPE 
tissues vs cfDNA) and method used (ddPCR vs FISH). cfDNA, cell free DNA; ddPCR, digital- droplet PCR; EGFR, epidermal growth factor receptor; FFPE, 
formalin- fixed paraffin embedded; FISH, fluorescent in situ hybridisation; ITT, intention to treat.
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Given the small number of EGFR- amplified cases in our trial 
cohort limited the statistical power of the analysis, we sought 
to validate our findings in an independent cohort of GEA. We 
screened the cBioportal for Cancer Genomics15 16 for local-
ised and metastatic GEA cases for whom EGFR amplification 
status was available. Our search returned data on 2122 samples 
from 2054 patients (online supplemental figure 2A) across 
11 non- overlapping studies. In line with our findings, EGFR- 
amplification was observed in approximately 6.5% of patients 
and was consistently associated with inferior OS, disease- specific 
survival, disease- free survival and PFS (online supplemental 
figure 2B- E) in the validation cohorts. Taken together these data 
strengthen the notion that EGFR- amplification may be a prog-
nostic biomarker in GEA.
EGFR CN in circulating cfDNA and prognosis in the REAL3 trial
EGFR CNV was determined by ddPCR in cfDNA for 354 
patients (table 2). In keeping with the results obtained from 
tissue, patients with EGFR- amplified disease had worse PFS 
(online supplemental table 9) and OS (figure 2; online supple-
mental table 10) compared with non- amplified cases. Patients 
with EGFR- amplified tumours exhibited a similar trend for 
worse PFS (online supplemental table 11) and OS (online supple-
mental table 12) also when survival analysis was conducted by 
treatment arm.
Combined analysis of the effect of EGFR CN and treatment on 
the outcome of patients in the REAL3 trial
EGFR CN gains extrapolated by tissue or cfDNA analyses were 
overall associated with worse outcome in the REAL3 ITT popu-
lation, consistent with the concept that EGFR amplification 
is an oncogenic driver in GEA. Interestingly, however, when 
conducted by treatment arm, our survival analyses revealed that 
the anti- EGFR mAb panitumumab did not mitigate this nega-
tive prognostic effect in patients with EGFR- amplification. In 
keeping with the detrimental effect of panitumumab observed 
in the ITT population,8 the combination of EGFR inhibition 
(EGFRi) and EOX chemotherapy was consistently associated 
with inferior outcome in both EGFR non- amplified (online 
supplemental table 13) and EGFR- amplified cases (online 
supplemental table 14). Despite the observation that adding 
panitumumab to EOX had a negative prognostic role in both 
groups, it was unexpected to notice that the negative association 
between EGFRi and EOX appeared more pronounced in patients 
whose tumour harboured an EGFR amplification (figure 3A; 
online supplemental table 14). Indeed, when the analysis was 
conducted among all the EGFR- amplified cases (based on plasma 
and cfDNA), the overall response rate was 78% in EOX vs 50% 
in EOX- P treated patients with a 6 months PFS of 71.4% (95% 
CI 44.7% to 100%) vs 39.8% (95% CI 24.1% to 65.9%) in 
EOX compared with EOX- P, respectively (online supplemental 
figure 3A,B).
Although the small number of patients in these subanal-
yses prevents drawing firm conclusions, it was interesting to 
notice that no benefit from EGFRi was observed even in cases 
with expected oncogene addiction due to significant levels of 
EGFR amplification (figure 3B). Given tyrosine kinase receptor 
coamplifications have been linked to benefit and resistance to 
EGFRi,17 we also tested cfDNA from EGFR- amplified patients 
treated with EOX- P who had a PFS greater than 6 months for 
potential drivers of response or resistance. Tissue (n=3) and 
circulating cfDNA (n=7) were available for 9 out of 10 patients, 
for one patient both tissue and circulating cfDNA were available 
(PT23). Low coverage whole- genome sequencing (online supple-
mental table 15) confirmed the presence of EGFR amplifications 
in all the cases with good correlation in CN between ddPCR and 
Table 1 Patient characteristics by treatment arm and EGFR status determined on tumour tissue (n=250)
EOX arm EOX- P arm
EGFR non- amplified (<2) EGFR amplified (≥2) EGFR non- amplified (<2) EGFR amplified (≥2)
Median age (IQR) 62.6 (54.2–68.4) 63.8 (54.3–68.6) 63.2 (56.6–69.7) 63.1 (59.0–65.4)
Males (%) 97 (80.8) 7 (100) 89 (78.8) 10 (100)
Females (%) 23 (19.2)    – 24 (21.2)    –
PS 0 (%) 44 (36.7) 4 (57.1) 42 (37.2) 5 (50)
PS 1 (%) 69 (57.5) 2 (28.6) 65 (57.5) 5 (50)
PS 2 (%) 7 (5.8) 1 (14.3) 6 (5.3)    –
Locally advanced (%) 8 (6.7)    – 10 (8.9) 1 (10)
Metastatic (%) 112 (93.3) 7 (100) 103 (91.1) 9 (90)
EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.
Table 2 Patients characteristics by treatment arm and EGFR status determined on cfDNA (n=354)
EOX arm EOX- P arm
EGFR non- amplified (<2) EGFR amplified (≥2) EGFR non- amplified (<2) EGFR amplified (≥2)
Median age (IQR) 62.8 (56.1–68.3) 60.8 (49.8–65.3) 63.4 (55.8–69.9) 62.7 (50.2–67.1)
Males (%) 139 (85.3) 3 (75) 138 (81.7) 16 (88.9)
Females (%) 24 (14.7) 1 (25) 31 (18.3) 2 (11.1)
PS 0 (%) 70 (42.9) 2 (50) 77 (45.6) 10 (55.5)
PS 1 (%) 82 (50.3) 2 (50) 85 (50.30) 7 (38.9)
PS 2 (%) 11 (6.8)     – 7 (4.1) 1 (5.6)
Locally advanced (%) 20 (12.3)    – 26 (15.4) 2 (11.1)
Metastatic (%) 143 (87.7) 4 (100) 143 (84.6) 16 (88.9)
cfDNA, cell- free DNA; EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.
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WGS (r2:0.82; p:0.003) for both tissue and plasma cfDNA. 70% 
of patients had coamplifications of receptor tyrosine kinase or 
other cancer- promoting genes, including MET, KRAS, FGFR1, 
IGFR1, SRC and VEGFA18–20, potentially associated with resis-
tance to EGFR- inhibitors (figure 3C). Interestingly, the VEGFA 
amplification was not detected in the tissue but only in plasma 
for PT23 (online supplemental figure 4). Taken together, these 
data suggest that some of the partial responses and favourable 
outcomes observed in EGFR- amplified cases treated with EOX- P 
were probably driven by the EOX chemotherapy backbone alone 
rather than by EGFRi.
Inferior outcome in GEA patients treated with panitumumab 
in combination with an epirubicin- containing chemotherapy 
regimen compared with chemotherapy alone, has also been 
reported by the AIO/CAO STO-0801 trial.21 Interestingly, a 
similar detriment was not observed in the EXPAND trial that 
investigated the addition of the anti- EGFR mAb cetuximab in a 
comparable chemotherapy backbone that excluded the anthracy-
cline component.7 Indeed, multiple lines of evidence suggest that 
anti- EGFR agents may be effective when combined with fluoro-
pyrimidines and platinum compounds for the treatment of meta-
static GEA cancers,2 9 but evidence advocating their combination 
with anthracyclines are lacking and, if anything, point towards 
an antagonistic effect between anthracyclines and EGFRi.22 
Based on these data and prompted by the unexpected effect of 
the combination between panitumumab and chemotherapy in 
EGFR- amplified cases in the REAL3 trial (figure 3A), we inves-
tigated a potential antagonistic effect between epirubicin and 
EGFRi in GEA patients.
PDOs model antagonisms between anthracyclines and EGFRi
The lack of commercially available EGFR- amplified GEA cancer 
cells lines has so far hindered the pre- clinical testing of EGFRi 
in gastric cancer. Hereafter, using EGFR- amplified and non- 
amplified PDOs established from metastatic gastric adenocarci-
nomas12 13 we provide experimental evidence of the antagonistic 
interaction between epirubicin and EGFRi in mGEA.
First, we modelled clinical observations2 9 reported in EGFR- 
amplified GEA patients treated with single agent EGFRi (EGFRi), 
in EGFR- amplified PDOs from metastatic gastro- oesophageal 
cancers (figure 4A) and we showed a significant effect on cell 
viability on treatment with single- agent anti- EGFR small mole-
cule gefitinib and, to a lesser extent, with the anti- EGFR mAb 
cetuximab (online supplemental figure 5A).
Next, we combined EGFRi with clinically relevant concen-
trations of epirubicin23 and we observed a consistent increase 
in cell viability selectively in EGFR- amplified PDOs, but not in 
EGFR diploid PDOs (figure 4B and online supplemental figure 
5B) or cell lines (online supplemental figure 6). In line with this, 
pathway analysis of RNA- seq data (online supplemental tables 
16 and 17, online supplemental figure 7) from EGFR- amplified 
PDOs treated with epirubicin alone or in combination with 
cetuximab, showed that the combination of the anthracycline 
and the anti- EGFR agent significantly downregulated several 
cell cycle- related genes, including the G1/S negative regulator 
p21 (encoded by CDKN1A) and the M phase- related cyclin 
B1 (encoded by CCNB1; figure 4C). Protein expression anal-
ysis of EGFR- amplified and non- amplified PDOs treated with 
epirubicin alone or in combination with cetuximab confirmed 
that the combinatorial treatment did induce a notable down-
regulation of both p21 and cyclin B1 proteins selectively in the 
former, coupled with increased levels of the S phase- promoting 
cyclin E1 (figure 4D). These data suggested that inhibition of 
EGFR signalling in an anthracycline treatment background may 
have a cell cycle- promoting effect in EGFR- amplified but not 
in EGFR- non- amplified gastric cancer cells. Indeed, the accel-
eration of cell cycle on the addition of cetuximab selectively 
in epirubicin- treated EGFR- amplified gastric cancer PDOs was 
further confirmed using a thymidine analog- based DNA incor-
poration FACS assay (figure 4E).
Nuclear EGFR has been reported to promote DNA repli-
cation and repair, and enhance the expression of various cell 
cycle- related genes by functioning as a cotranscription factor.24 
We, therefore, tested whether nuclear EGFR is involved in the 
Figure 2 Overall survival (OS) based on EGFR- amplification in the REAL3 trial. EGFR CN was determined using ddPCR on pretreatment cfDNA. 
Kaplan- Meier curves show the OS of patients based on the presence/absence of EGFR CN. cfDNA=cell free DNA; CN, copy number; ddPCR, digital- 
droplet PCR; EGFR, epidermal growth factor receptor;
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Figure 3 Clinical outcome by treatment arm in EGFR- amplified cases enrolled in the REAL3 trial. (A) Bars show OS and PFS (median±SE) in EGFR- 
amplified patients treated with chemotherapy alone (EOX) or chemotherapy plus panitumumab (EOX- P). Similar trends are observed when a cut- off 
of two or five EGFR copies is used. (B) Blue bars indicate PFS, orange bars indicate EGFR copies determined by ddPCR in plasma cfDNA (graph on 
the top) or tissue (bottom). (C) Plots show copy number changes in EGFR (blue) and other receptor tyrosine kinase genes (red) in patients with PFS 
greater than 6 months on treatment with EOX- P. Values outside of the y- axis limits are plotted at the limit. cfDNA, cell- free DNA; CN, copy number; 
ddPCR, digital- droplet PCR; EGFR, epidermal growth factor receptor; EOX, epirubicin+oxaliplatin+capecitabine; OS, overall survival; P, panitumumab; 
PFS, progression- free survival.
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Figure 4 Effect of epirubicin or epirubicin plus EGFR inhibitors in EGFR- amplified and non- amplified patient- derived organoids. (A) EGFR FISH 
images, demonstrating gain of copies and diploid status in the F-014 BL and DD191 human GEA PDO lines, respectively. (B) Concentration- dependent 
effect of epirubicin as a monotherapy or in combination with a stable dose of two different anti- EGFR agents (cetuximab, 20 µg/mL; gefitinib, 200 nM) 
in the EGFR- amplified F-014 BL and EGFR- diploid DD191 human GEA PDO lines. The combination of low epirubicin concentrations with anti- EGFR 
treatments results in a paradoxical increase in viability selectively in the EGFR- amplified F-014 BL GEA PDO line. Viability data shown are means±SEM 
of indicated independent experiments. (C) Pathway analysis of RNAseq data from the EGFR- amplified F-014 BL GEA PDO line treated with a low 
concentration of epirubicin alone or in combination with cetuximab for 24 hours revealed a significant reduction in the expression of cell cycle- related 
genes associated with the epirubicin and cetuximab combination. RNA from three independent biological replicates were sequenced per condition. 
(D) Protein analysis of the EGFR- amplified F-014 BL and EGFR- diploid DD191 human GEA PDO lines treated with two low concentrations of epirubicin 
alone or in combination with cetuximab for 24 hours. In line with RNAseq data, a reduction in p21 and cyclin B1 protein levels was observed when 
epirubicin was combined with inhibition of EGFR and downstream MAPK and AKT signalling specifically in the EGFR- amplified organoid line. (E) 
EdU DNA incorporation assay following treatment of the EGFR- amplified F-014 BL and EGFR- diploid DD191 human GEA PDO lines with two low 
concentrations of epirubicin alone or in combination with cetuximab for 24 hours. The addition of cetuximab antagonises the antiproliferative effect of 
epirubicin and accelerates DNA synthesis specifically in the EGFR- amplified organoid line. (F) Proposed model of antagonism between epirubicin and 
anti- EGFR treatments in EGFR- amplified GEA. EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; FSC- A; forward scatter- 
area; GEA, gastro- oesophageal adenocarcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; PDO, patient- derived organoid.
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increase in proliferation observed in the EGFR- amplified PDOs 
in response to the epirubicin and anti- EGFR combinatorial 
treatment. Interestingly, cetuximab, both as a single agent and in 
combination with epirubicin, increased EGFR protein stability, 
leading to increased EGFR nuclear localisation; however, this 
cetuximab- mediated increase of nuclear EGFR was observed in 
both PDOs regardless of their EGFR CN status (online supple-
mental figure 8).
Taken together, our observations suggest that inhibition of 
EGFR signalling in a background of epirubicin treatment selec-
tively induces the downregulation of the G1/S negative regu-
lator p21 and the upregulation of the S phase- promoting cyclin 
E1 in EGFR- amplified gastric cancer PDOs, thereby leading to 
increased flux to the S phase of the cell cycle. Cyclin E1 upregu-
lation has been linked to shortened mitosis and increased mitotic 
exit.25 These observations, together with decreased levels of M 
phase- associated proteins observed when epirubicin is combined 
with cetuximab (figure 4D), suggest that inhibition of EGFR 
in a background of epirubicin treatment may also speed up the 
M- to- G1 transition in EGFR- amplified PDOs, thereby leading 
to an overall accelerated progression through the cell cycle 
(figure 4F). Increased nuclear localisation of EGFR was observed 
in cells treated with the combination of epirubicin and cetux-
imab irrespective of EGFR status and, this phenomenon, might 
partially explain the detrimental effect caused by the addition to 
panitumumab to EOX in the REAL3 trial population. The acti-
vation of additional cotranscriptional factors in EGFR- amplified 
cases might account for the paradoxical effect observed specifi-
cally in this subgroup of patients.
DISCUSSION
In this study, using ddPCR performed on routine diagnostic 
biopsies obtained from oesophagogastric cancer patients treated 
in the REAL3 trial, we identify a 7% prevalence of patients with 
EGFR- amplified tumours, which is consistent with the litera-
ture.1–3 We demonstrate that EGFR analysis in plasma is comple-
mentary to EGFR amplification detection in tumour tissue, and 
EGFR amplification appears associated with poor prognosis, 
even though these data are not statistically significant likely due 
to the small number of EGFR- amplified cases. Our results also 
suggest that EGFR- amplified tumours did not benefit from anti- 
EGFR therapy in combination with chemotherapy; in fact, both 
our clinical and preclinical data suggest an antagonistic effect 
between anthracyclines and anti- EGFRi, with potential implica-
tions for the design of future drug combination trials.
EGFR amplification is observed in 6%–10% of gastric 
and gastro- oesophageal cancers across multiple datasets, and 
is recognised as negatively prognostic in surgically treated 
patients.26–28 However, the association between EGFR amplifica-
tion and outcome in patients with metastatic gastro- oesophageal 
cancer treated with cytotoxic chemotherapy in the context of a 
clinical trial has not been previously described. In the perioper-
ative phase II randomised AIO/CAO STO-0801 trial assessing 
the addition of panitumumab to perioperative epirubicin, 
cisplatin and capecitabine chemotherapy in unselected patients 
with resectable gastro- oesophageal cancer, both EGFR overex-
pression or gene amplification were negatively prognostic for 
survival, independent of treatment arm.21 Interestingly, the HR 
for OS in AIO/CAO STO-0801 which used an almost identical 
chemotherapy regimen (ECX) and the same anti- EGFR therapy 
as REAL3 (panitumumab) was strikingly similar to the REAL3 
results (ECX- P vs ECX HR 1.37, 95% CI 0.84 to 2.25, p=0.2). 
However, this result lacks statistical power due to the relatively 
modest size of the AIO/CAO STO-0801 trial (n=160). Notably, 
the EXPAND trial which investigated the addition of cetuximab 
to cisplatin and fluoropyrimidine chemotherapy did not use an 
anthracycline and did not demonstrate a significant detriment 
to anti- EGFR therapy.7 Furthermore, in EXPAND patients 
with the highest levels of EGFR protein expression appeared 
to have an increased benefit from cetuximab.7 29 Although our 
data and the retrospective analyses of AIO/CAO STO-0801 and 
EXPAND trials are based on small numbers of patients with 
EGFR- amplified cancers, they are provocative as, taken together, 
suggest a negative interaction between anti- EGFR therapy and 
anthracyclines in EGFR- amplified GEA.
Although first generation anti- EGFR trials in unselected GEA 
patients were negative, hints regarding the potential efficacy 
of anti- EGFR therapy in biomarker- selected populations have 
recently emerged in the literature.2 9 30 For example, although 
the COG study of gefitinib compared with best supportive care 
in unselected previously treated oesophageal cancer patients did 
not show a benefit in survival for gefitinib, post hoc biomarker 
analysis using FISH for EGFR CN has suggested a significant 
survival benefit for EGFR- amplified tumours (OS benefit for 
gefitinib in EGFR- amplified HR=0.21, 95% CI 0.07 to 0.64; 
p=0.006).9 11 30 Similarly, in a study evaluating multiple EGFRi 
including ABT-806 and cetuximab in EGFR- amplified gastro- 
oesophageal cancers, several profound responses to single agent 
anti- EGFR therapy were observed (objective response rate 57%) 
and the median PFS for patients treated with anti- EGFR therapy 
alone and in combination was 10 months2 and largely surpassed 
the benefits of standard cytotoxic chemotherapy in gastro- 
oesophageal cancer.
Heterogeneity of biomarker expression is common in gastro- 
oesophageal cancer, and can impact significantly on the efficacy 
of targeted therapy and trial results.10 31 32 It is possible that 
ctDNA sampling may overcome some of the challenges associ-
ated with tissue heterogeneity as we have previously shown in 
colorectal cancer,33 however, ctDNA may not be present in all 
gastro- oesophageal cancer patients as its load relates to tumour 
burden.34 In keeping with this observation, higher ctDNA concen-
trations were observed in metastatic compared with locally 
advanced patients in our analysis. Detection of gene amplifica-
tion in plasma has been suggested to be prognostic for targeting 
HER2 and FGFR2- amplified gastro- oesophageal tumours31 35 
and screening for multiple simultaneous amplifications might 
have important implications. 70% of EGFR- amplified patients 
tested by WGS in our study showed coamplification in other 
targetable oncogenes such as MET. Future studies using targeted 
approaches such as nanoString nCounter technology or low- pass 
WGS might further classify patients into three categories: (1) 
those whose tumours do not harbour coamplifications and are 
more likely to benefit from EGFRi; (2) those that carry targ-
etable coamplifications that can be therapeutically exploited 
in anti- EGFR drug combinations; (3) those with undruggable 
coamplifications such those in EGFR and KRAS that are less 
likely to benefit from EGFRi alone.
The optimal cut- off for sensitivity to anti- EGFR therapy 
and the value of targeting this axis in EGFR- amplified gastro- 
oesophageal cancer have not yet been fully delineated: Maron 
et al observed responses to anti- EGFR therapy in patients with 
EGFR CN over the 50th percentile (2.4 copies in plasma).2 
However, it is plausible that higher levels of EGFR amplification 
(and as such oncogene addiction) could enrich future trials for 
patients more likely to respond to anti- EGFR therapy.
A potential limitation of this study is that approximately 
half of REAL3 tumours had tissue available for amplification 
9Smyth EC, et al. Gut 2020;0:1–10. doi:10.1136/gutjnl-2020-322658
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testing as many samples were used in previous biomarker 
studies.36 37 Specifically, small numbers of EGFR- amplified cases 
were included in the survival analyses limiting the power of 
this work. That being said, it is worth considering that: (1) the 
prognostic trend for EGFR amplification was also confirmed in 
liquid biopsies (available for 65% of the ITT cohort) and 200 
patients in this analysis did not overlap with those presented 
for tissue analysis and (2) in multivariate analyses, the effect of 
EGFR amplification on survival appeared to be consistent when 
adjusted for potential confounders. The second potential limita-
tion of our study is the a priori difference in chemotherapy dose 
and in survival between the arms of the trial. Patients treated in 
the EOX- P arm of REAL3 received a dose reduction of oxal-
iplatin and capecitabine chemotherapy following the results 
of a safety run- in study. However, we performed our analyses 
both in the ITT population and by treatment arm in an effort 
to mitigate this difference. A third consideration relates to the 
negative interaction between panitumumab and other chemo-
therapy agents in the REAL3 trial. Indeed, conflicting results 
are available on the negative interaction between oxaliplatin 
and cetuximab in metastatic colorectal cancer patients.38–40 
The observation that a reduction in reactive oxygen species in 
response to cetuximab treatment can impair oxaliplatin- induced 
apoptosis provides a biological explanation for these clinical 
observations.41 Whether this hypothesis contributes to explain 
the inferior outcome observed in EOX- P treated patients in the 
REAL3 trial remains to be confirmed. However, given durable 
responses to FOLFOX+ cetuximab have been observed in 
EGFR- amplified metastatic gastro- oesophageal cancer patients2 
and chemotherapy regimens containing anthracyclines in combi-
nation with panitumumab have been consistently associated 
with inferior outcomes compared with chemotherapy alone,8 42 
we focused our preclinical analysis on the antagonism between 
epirubicin and EGFRi.
In conclusion, herein, we present results that suggest that 
EGFR status can be measured using ddPCR in tumour and 
plasma in a cost- effective way and that EGFR amplification is 
associated with a negative survival outcome in patients with 
GEA independent of treatment arm. Our results also emphasise 
the challenge in designing optimal drug combinations in absence 
of robust patient- centred preclinical models. In view of the rela-
tively rarity of EGFR- amplified gastro- oesophageal cancers, we 
suggest that international collaborative efforts may be required 
in order to facilitate prospective trials enriched for EGFR- 
amplified tumours based on liquid biopsy testing.
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